Palmitoyl tripeptide-8 turns up on the ingredient lists of serums and creams sold for sensitive, reactive or “stressed” skin, usually among several other peptides. Its sequence is the more interesting story: the three amino acids at its centre are the working core of the hormone that tans skin, and of two FDA-approved drugs built from that hormone. This page sets out what the molecule is, what the five indexed papers on it contain, as of 22 October 2026, and what that record can and cannot support.
Three amino acids, one fatty acid
PubChem's record (CID 11498521) gives the structure in full: palmitoyl–histidine–D-phenylalanine–arginine amide, formula C37H61N9O4, 695.9 daltons. Read piece by piece:
- Palmitoyl is a 16-carbon fatty acid on the front. It is the same lipid tag carried by Matrixyl's peptides and by palmitoyl tripeptide-5, added to help a water-loving peptide move into the skin's oily outer layer.
- His–(D)Phe–Arg is the peptide itself. The phenylalanine is the D-form, the mirror image of the one the body uses in its own proteins. Chemists make that swap to slow down the enzymes that would otherwise cut a peptide apart.
- Amide on the end is another common protective cap.
At about 696 daltons it is above the roughly 500-dalton size often quoted as the easy limit for passing the skin barrier, which is the reason the fatty acid is there. No paper we found measured how much of it reaches living skin.
Where the sequence comes from
Alpha-MSH, the 13-amino-acid hormone that makes pigment cells switch to dark pigment, reads Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val. The His-Phe-Arg run at positions 6 to 8 is part of the stretch the receptor recognises; the receptor and its job are covered on our alpha-MSH and melanocortin receptors page.
The drugs made from alpha-MSH keep that run and make the same D-phenylalanine substitution. The FDA label for afamelanotide gives Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (see our afamelanotide and Scenesse page), and bremelanotide's label gives a seven-residue, partly ring-shaped molecule that also contains His-(D)Phe-Arg (compared on our MT1 vs MT2 page). Palmitoyl tripeptide-8 is those three residues, cut down and given a fatty acid.
Sharing a core is not the same as sharing an effect. The drugs are 7 to 13 amino acids long, keep the tryptophan that follows arginine in the hormone, and are injected or implanted. The cosmetic peptide stops at arginine, is applied to the surface, and is used at the low levels typical of cosmetic peptides. Its suppliers position it as calming rather than pigmenting. But the overlap explains why the literature on it keeps returning to the melanocortin receptors, and why one research group used it as a key to reach pigment cells.
The five papers
PubMed held five records naming palmitoyl tripeptide-8 on 22 October 2026, the same five under the quoted name and the unquoted field-tagged form. As a control, the same method returned 44 for acetyl hexapeptide-8 or Argireline. None of the five is tagged as retracted.
| Paper | What it is | Does it test the peptide alone on people? |
|---|---|---|
| Resende et al. 2021, Pharmaceuticals, University of Porto | Review of the peptides in 88 facial products for sensitive skin from multinational brands | No — a review. Peptides were in 17% of the products; the authors found the supporting data “mostly” in patents and supplier brochures |
| Ferreira et al. 2022, Int J Cosmet Sci, University of Porto | Ranking of the actives in the same 88 products | No — names palmitoyl tripeptide-8 as “designed to act on the molecular targets” of sensitive skin; only three actives had been studied in people with sensitive skin, and this was not one of them |
| Marianni et al. 2024, Int J Pharm Compd, Fagron BV | Stability of prescription drugs (adapalene, dapsone, hydroquinone) mixed into Fagron's Cleoderm cream base, which contains the peptide | No — a chemistry and shelf-life study; authors employed by Fagron |
| Cheng et al. 2025, Colloids Surf B, Guyu Biotechnology | Liposomes carrying glabridin, a liquorice-root lightening compound, with palmitoyl tripeptide-8 on the surface to target pigment cells | No — the peptide is a targeting tag; tested in cell cultures and “in vivo”, with no human trial in the abstract |
| Polonini et al. 2025, Curr Issues Mol Biol, Fagron BV and Gap Biotech | Cleoderm base tested on co-cultured human skin cells: lower inflammatory signals and matrix-degrading enzymes | No — a whole base with a plant extract, bisabolol, hyaluronic acid and oils; Fagron employee author and Fagron funding declared |
A sixth record turns up under the shorter “tripeptide-8”: a September 2026 series of eight post-procedure cases using a PDRN serum whose formula includes a “tripeptide-8” (PMID 42696342). It describes eight women in a split-face, real-world protocol, gives no comparison of the serum with and without the peptide, and does not say whether the ingredient is the palmitoylated form.
What the five have in common: none puts palmitoyl tripeptide-8 by itself on a person's skin and measures anything. The human-relevant results all come from mixtures, delivery systems or cell cultures, and two of the five are written by a company describing its own product base.
The pigment-cell paper, read closely
The Guyu study is the one that touches the sequence's origin. Its authors attached palmitoyl tripeptide-8 to the outside of liposomes so that they would latch on to MC1R, the alpha-MSH receptor on pigment cells. They report that the liposomes were taken up 1.9 times more by pigment cells than by fibroblasts and 3.4 times more than by surface skin cells, and that the formula “could competitively bind to MC1R in the presence of α-MSH”, reducing the receptor's signal. The combined liposome lightened more than glabridin alone or glabridin simply mixed with the peptide.
That is evidence that the tripeptide can find the receptor its sequence came from. It is not evidence about what a serum containing it does to skin colour, because the paper did not test the peptide alone for lightening or darkening, and it did not study people. No published study reports palmitoyl tripeptide-8 changing human skin colour in either direction.
The sensitive-skin claim
The ingredient is sold to calm skin. The Porto reviews are the fairest summary of what supports that: it was designed with sensitive-skin targets in mind, and the evidence sits in documents that are not peer-reviewed or independently checkable. The one human sensitive-skin study those reviews could find for any peptide was of a different molecule, acetyl dipeptide-1 cetyl ester. For the wider picture of peptides and reactive conditions, our peptides and rosacea and peptides and eczema pages count the trials.
On labels
The peptide usually appears as one of several. COSRX's The 6 Peptide Skin Booster Serum declares it 12th of 44, the last of six consecutive peptides; our Korean peptide serum census lists it among the peptides on K-beauty labels. No brand we have read states its concentration, and US labels may list anything at 1% or less in any order, so the position is a rough guide at best.
What can fairly be said
Palmitoyl tripeptide-8 is a lipid-tagged fragment of the tanning hormone, chosen by suppliers for calming claims. Its sequence connects it to a receptor and a family of drugs with a long, documented record. Its own record is five papers, none a human test of the ingredient, two written by a company about its own base. A product that lists it contains it; what it does in that product, at that level, has not been published.
Sources
Opened 22 October 2026: PubChem CID 11498521 (structure, formula, weight); PubMed searches "palmitoyl tripeptide-8" (5), palmitoyl tripeptide-8[tiab] (5), tripeptide-8[tiab] (6), control "acetyl hexapeptide-8" OR argireline (44), and the retraction filter (0); abstracts and conflict statements of PMIDs 34451799, 34813665, 39405570, 40712492, 41614884 and 42696342. Afamelanotide and bremelanotide sequences as given on their FDA labels, quoted on the linked pages. Corrections go to the contact page.